Reuters logo
4 个月内
BRIEF-Jazz pharmaceuticals and Nippon Shinyaku enter into license agreements for development and commercialization of Defitelio and Vyxeos in Japan
2017年3月30日 / 早上6点26分 / 4 个月内

BRIEF-Jazz pharmaceuticals and Nippon Shinyaku enter into license agreements for development and commercialization of Defitelio and Vyxeos in Japan

1 分钟阅读

March 30 (Reuters) - Jazz pharmaceuticals:

* Jazz Pharmaceuticals Plc - co and Nippon Shinyaku enter into license agreements for development and commercialization of Defitelio and Vyxeos in Japan

* Jazz Pharmaceuticals - will manufacture, supply Defitelio and Vyxeos to Nippon Shinyaku; will receive revenue based on percent of product sales in Japan Source text for Eikon: Further company coverage: (Bengaluru Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below